The Class I Phosphoinositide 3-kinases (PI3Ks) regulate a wide range of cellular functions, including growth and survival, metabolism, lipid and protein synthesis, and motility. Of the Class I enzymes, only PI3K? is regulated both by receptor tyrosine kinases (RTKs) and G-protein coupled receptors (GPCRs), the latter through direct binding of the PI3K? catalytic subunit (p110?) to G?? subunits. We recently provided the first mechanistic information about GPCR regulation of PI3K?, by identifying and mutating the p110? binding site for G??. Surprisingly, many of the cellular activities of PI3K?, including its abilityto transform fibroblasts and to support the growth of PTEN-null tumor cells, require its interactions with G?? subunits. Moreover, when we replace endogenous p110? with a GPCR-uncoupled mutant in breast tumor cells, the cells show decreased in vitro 3D invasion, decreased tumor growth in an orthotopic model, and decreased metastasis in an in vivo metastasis assay. Notably, disrupting GPCR inputs to PI3K? caused a greater decrease in tumor growth than eliminating PI3K? lipid kinase activity. These data suggest that GCPR coupling to PI3K? plays critical roles in tumor development and metastasis. This coupling could provide an important new drug target for cancer chemotherapy. In addition to G??, p110? also binds the small GTPase Rab5. We identified and mutated the Rab5 binding site in p110?. Cells expressing Rab5-uncoupled p110? show pronounced defects in macropinocytosis, a clathrin-independent endocytic process used by tumor cells to obtain nutrients that support rapid growth. These data suggest that Rab5-PI3K? interactions could provide a novel drug target for some tumors. Finally, published studies have shown that the PTEN tumor suppressor forms a complex with p110? in cells, whereas in vitro data shows that PTEN preferentially binds dimers of the p85 regulatory subunit. These data appear to be incompatible, as p85 is not thought to dimerize when bound to p110 catalytic subunits. We have developed novel tools for manipulating the multimeric state of p85, which we can use to define how p85 and p110? interact with PTEN.
Specific Aim 1 examines GPCR signaling to PI3K? in mouse models of prostate and endometrial cancer, using conditional and whole animal knock-ins of mutant p110?.
Aim 2 proposes mechanistic studies on the regulation of macropinocytosis by Rab5-PI3K? interactions, and examines the role of Rab5-p110? binding in dendritic cell function and in a K-Ras-driven model of pancreatic cancer. Finally, Aim 3 uses analytical ultracentrifugation, which measures the molecular weight of oligomers independently of shape, to define interactions between PTEN and PI3Ks. Taken together, we have identified novel mutants, made novel biological tools, and devised new experimental strategies, to better define the role of PI3K? in cell biology and human disease.

Public Health Relevance

PI 3-kinases are intracellular enzymes that play an important role in cell proliferation and survival, and which frequently contain activating mutations in human cancers. Understanding the mechanisms that regulate their activity in normal and malignant cells is critical for the design of novel and specific drugs to target these enzymes in human disease.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Molecular and Integrative Signal Transduction Study Section (MIST)
Program Officer
Dunsmore, Sarah
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Albert Einstein College of Medicine
Schools of Medicine
United States
Zip Code
Norwood Toro, Laura E; Wang, Yarong; Condeelis, John S et al. (2018) Myosin-IIA heavy chain phosphorylation on S1943 regulates tumor metastasis. Exp Cell Res 370:273-282
Bresnick, Anne R (2018) S100 proteins as therapeutic targets. Biophys Rev 10:1617-1629
Bilanges, Benoit; Alliouachene, Samira; Pearce, Wayne et al. (2017) Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism. Nat Commun 8:1804
Erami, Zahra; Khalil, Bassem D; Salloum, Gilbert et al. (2017) Rac1-stimulated macropinocytosis enhances G?? activation of PI3K?. Biochem J 474:3903-3914
Houslay, Daniel M; Anderson, Karen E; Chessa, Tamara et al. (2016) Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3K? in myeloid cells. Sci Signal 9:ra82
Backer, Jonathan M (2016) The intricate regulation and complex functions of the Class III phosphoinositide 3-kinase Vps34. Biochem J 473:2251-71
Khalil, Bassem D; Hsueh, Christine; Cao, Yanyan et al. (2016) GPCR Signaling Mediates Tumor Metastasis via PI3K?. Cancer Res 76:2944-53
Salamon, Rachel S; Dbouk, Hashem A; Collado, Denise et al. (2015) Identification of the Rab5 binding site in p110?: assays for PI3K? binding to Rab5. Methods Mol Biol 1298:271-81
Braccini, Laura; Ciraolo, Elisa; Campa, Carlo C et al. (2015) PI3K-C2? is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling. Nat Commun 6:7400
LoPiccolo, Jaclyn; Kim, Seung Joong; Shi, Yi et al. (2015) Assembly and Molecular Architecture of the Phosphoinositide 3-Kinase p85? Homodimer. J Biol Chem 290:30390-405